Table 3.
IBV lineages in Middle Eastern and North African countries in the past 10 years (2010-2020)
| Country | Number of isolates | Lineage | Sequence availability | References | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GI-1 | GI-12 | GI-13 | GI-16 | GI-19 | GI-21 | GI-23 | New unclassified lineage | ||||
| Egypt | 295 | 23 (7.8%) | 12 (4.1%) | 11 (3.7%) | 4 (1.4%) | 1 (0.3%) | 0 | 244 (82.7%) | 0 | Yes | [43–45, 93, 128] |
| Algeria | 4 | 0 | 0 | 1 (25%) | 0 | 0 | 0 | 0 | 3 (75%) | Yes | [73, 75] |
| Libya | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 12 (100 %) | Yes | [79] | |
| Morocco | 57 | 35(61.4%) | 0 | 3 (5.3%) | 0 | 1 (1.8%) | 18 (31.6 %) | 0 | 0 | Yes | [72] |
| Tunisia | 7 | 0 | 0 | 0 | 5 (71.4%) | 0 | 0 | 0 | 2 (28.6%) | Yes | [77, 83] |
| Jordan | 27 | 9 (33.3%) | 0 | 6 (22.2%) | 1 (3.7%) | 0 | 0 | 11 (40.7%) | 0 | Yes | [50, 53] |
| Lebanon | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (100%) | 0 | Yes | Direct submission (NCBI) |
| KSA | 53 | 12 (22.6%) | 0 | 17 (32.1%) | 12 (22.6%) | 0 | 0 | 12 (22.6%) | 0 | Yes | [50, 58] |
| Oman | 34 | 2 (5.9%) | 2 (5.9%) | 28 (82.4%) | 0 | 0 | 0 | 2 (5.9%) | 0 | Yes | [59] |
| Iran | 359 | 33 (9.2%) | 2 (0.6%) | 78 (21.7%) | 2 (0.6%) | 39 (10.9%) | 0 | 200 (55.7%) | 5 (1.4%) | Yes | [68] |
| Iraq | 46 | 1 (2.2%) | 0 | 14 (30.4%) | 0 | 3 (6.5%) | 0 | 28 (60.9%) | 0 | Yes | [54] |
| Israel | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (100%) | 0 | Yes | Direct submission (NCBI) |
| Syria | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 10 (100%) | 0 | Yes | Direct submission (NCBI) |
| Turkey | 73 | 9 (12.3%) | 0 | 7 (9.6%) | 0 | 0 | 0 | 57 (78.1%) | 0 | Yes | [81, 82] |